Brief: Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt
09/02/2026 14:41
Feb 9 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ® PDT FOR ACTINIC KERATOSES ON THE EXTREMITIES, NECK, AND TRUNK, MEETING PRIMARY ENDPOINT BIOFRONTERA INC - PRIMARY ENDPOINT ACHIEVED WITH COMPLETE CLEARANCE RATE OF AK LESIONS BIOFRONTERA INC - AMELUZ PDT ACHIEVES 45.6% CLEARANCE RATE IN PHASE 3 STUDY BIOFRONTERA INC - AK LESION CLEARANCE 73.1% IN FAS AND 80.3% IN PPS BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026 Source text: ID:nGNX7gV97j Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales